Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Current Cancer Drug Targets is Scopus-indexed (Q2, CiteScore 4.2), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Bentham Science Publishers.
Checked against the index lists dated .
ISSN 1568-0096Verify ISSN ↗1873-5576Verify ISSN ↗
Publisher: Bentham Science Publishers
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 204 / 428 | 52nd | Q2 |
| Pharmacology | 174 / 328 | 47th | Q3 |
| Drug Discovery | 94 / 161 | 41st | Q3 |
| Cancer Research | 151 / 233 | 35th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2001–present, best quartile Q2, CiteScore 4.2.
Current Cancer Drug Targets is Q2 in Oncology (rank 204 of 428), Q3 in Pharmacology (rank 174 of 328) and Q3 in Drug Discovery (rank 94 of 161), by CiteScore 2025. It is ranked in 4 subject areas in all.
Current Cancer Drug Targets is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.2, which places it in quartile Q2 at the 52nd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.726, quartile Q2, with an H-index of 109.
Current Cancer Drug Targets is published by Bentham Science Publishers. Its print ISSN is 1568-0096 and its online ISSN is 1873-5576.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Current Cancer Drug Targets has an h-index of 115 and a 2-year mean of 1.95 citations per paper (OpenAlex). Its Scopus CiteScore is 4.2, quartile Q2. On 2-year citations it ranks #202 of 424 Scopus journals in Oncology.
Current Cancer Drug Targets published 125 papers in 2025; its busiest recent year was 2024 with 143. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2026), authors are most often from China (60.3%), India (14.7%) and Iran (3%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.